Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.43 |
| ▸ | HTR3B | O95264 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15215812 | 0.84 | LGALS9 (0.45) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL12069028 | 0.84 | LGALS9 (0.45) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL803313 | 0.80 | CHRM2 (0.40) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL9469882 | 0.76 | LGALS9 (0.46) | CHRM2CHRM4CHRM1CHRM3HTR3E | |
| SCHEMBL16311866 | 0.76 | CHRM2 (0.56) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL19228658 | 0.75 | CHRM2 (0.48) | CHRM2CHRM4CHRM1CHRM3HTR3E | |
| SCHEMBL12347869 | 0.75 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL12347855 | 0.75 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL12103794 | 0.73 | BCHE (0.49) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL10240925 | 0.73 | CHRM2 (0.44) | CHRM2CHRM4CHRM1CHRM3HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481550-B2 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120071482-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071482-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | CHRM2 3901/4885CHRM4 4016/4885CHRM1 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.